168 related articles for article (PubMed ID: 19305144)
1. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Fernandez-Vidal A; Mazars A; Gautier EF; Prévost G; Payrastre B; Manenti S
Cell Cycle; 2009 May; 8(9):1373-9. PubMed ID: 19305144
[TBL] [Abstract][Full Text] [Related]
2. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
[TBL] [Abstract][Full Text] [Related]
3. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
[TBL] [Abstract][Full Text] [Related]
4. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
6. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
[TBL] [Abstract][Full Text] [Related]
7. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
Colomba A; Courilleau D; Ramel D; Billadeau DD; Espinos E; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2008 Apr; 27(19):2728-36. PubMed ID: 17998938
[TBL] [Abstract][Full Text] [Related]
8. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
[TBL] [Abstract][Full Text] [Related]
9. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
[TBL] [Abstract][Full Text] [Related]
10. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
11. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
12. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
[TBL] [Abstract][Full Text] [Related]
13. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B
Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642
[TBL] [Abstract][Full Text] [Related]
14. Pathobiology of ALK+ anaplastic large-cell lymphoma.
Amin HM; Lai R
Blood; 2007 Oct; 110(7):2259-67. PubMed ID: 17519389
[TBL] [Abstract][Full Text] [Related]
15. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
16. NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis.
McDonnell SR; Hwang SR; Basrur V; Conlon KP; Fermin D; Wey E; Murga-Zamalloa C; Zeng Z; Zu Y; Elenitoba-Johnson KS; Lim MS
Oncogene; 2012 Aug; 31(32):3733-40. PubMed ID: 22179823
[TBL] [Abstract][Full Text] [Related]
17. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
18. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
Staber PB; Vesely P; Haq N; Ott RG; Funato K; Bambach I; Fuchs C; Schauer S; Linkesch W; Hrzenjak A; Dirks WG; Sexl V; Bergler H; Kadin ME; Sternberg DW; Kenner L; Hoefler G
Blood; 2007 Nov; 110(9):3374-83. PubMed ID: 17690253
[TBL] [Abstract][Full Text] [Related]
19. C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.
Anastasov N; Bonzheim I; Rudelius M; Klier M; Dau T; Angermeier D; Duyster J; Pittaluga S; Fend F; Raffeld M; Quintanilla-Martinez L
Haematologica; 2010 May; 95(5):760-7. PubMed ID: 20015877
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]